← All trials
NCT06644040
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 25, 2024
- Primary completion
- Dec 30, 2024
- Completion date
- May 31, 2025
- First posted
- Oct 16, 2024
- Last posted
- Nov 29, 2024
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- QuadMedicineLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.